Cadre Holdings (CDRE): Valuation Check After $50 Million DoD Contract Win for Med-Eng

Cadre Holdings (CDRE) just landed a meaningful win, with its Med-Eng subsidiary securing a five year, $50 million contract from the US Department of Defense for blast exposure monitoring systems.

See our latest analysis for Cadre Holdings.

The deal comes on top of a strong run, with the share price at $41.61 and a year-to-date share price return of about 29 percent, while the three-year total shareholder return of roughly 114 percent signals that momentum has been building rather than fading.

If this kind of defense win has your attention, it could be a good moment to explore other opportunities across aerospace and defense stocks as you refine your watchlist.

But with shares already up strongly and trading about 17 percent below consensus targets despite solid revenue and earnings growth, is Cadre still a bargain, or has the market already priced in its next leg of expansion?

Most Popular Narrative Narrative: 14.2% Undervalued

With Cadre’s fair value pegged at $48.50 against a $41.61 close, the leading narrative sees more upside anchored to long term structural demand.

The company's robust pipeline of high margin M&A targets, paired with disciplined capital allocation, is expected to drive scale, operational leverage, and long term adjusted EBITDA growth, with free cash flow generation supporting both organic growth and shareholder returns.

Read the complete narrative.

Curious what kind of revenue climb and profit uplift this vision is built on? The narrative leans on ambitious earnings expansion and a future multiple that assumes investors reward Cadre like a premium growth compounder. Want to see the specific forecasts behind that confidence?

Result: Fair Value of $48.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, if there are extended contract delays or execution hiccups in the nascent nuclear segment, those upbeat growth and valuation assumptions could quickly be tested.

Find out about the key risks to this Cadre Holdings narrative.

Build Your Own Cadre Holdings Narrative

If the prevailing storyline does not quite fit your view, you can dig into the numbers yourself and craft a personalized narrative in minutes, Do it your way.

A great starting point for your Cadre Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Use the Simply Wall St Screener to quickly surface fresh opportunities tailored to your strategy, so you are not relying on the same crowded ideas as everyone else.

• Capitalize on mispriced quality by targeting companies that look cheap on future cash flows through these 899 undervalued stocks based on cash flows before the wider market catches on.
• Ride the wave of automation and productivity gains by focusing on innovators powering intelligent software and infrastructure using these 24 AI penny stocks.
• Strengthen your income stream by hunting for reliable payouts and potential price upside with these 12 dividend stocks with yields > 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com